High capital allocations, low public relations. Long gestation businesses, short decision cycles. High absolute returns, low-to-nil asset attachment. This, in a nutshell, is Arun Kumar’s business philosophy. For someone who’s created three public pharma companies, incubated several smaller entities, and seals a new deal sooner than the ink on the previous one has dried, Kumar’s is an unusual wealth generation machine. One that is now being oiled for a different run.

Consider this: Bengaluru-based Strides Pharma Science Ltd grossed Rs 79.9 crore ($11.5 million) in profit (before tax) from continuing operations, but an eye-rolling Rs 625.8 crore ($90 million) profit from discontinued operations in the year ended March 2018. The 29-year-old public company, Kumar’s first, had consolidated revenues of Rs 2,857 crore ($412 million) in the same year.

It’s a similar story at SeQuent Scientific Ltd (SSL), India’s largest animal health company by far; also the second public company from Kumar’s stable. Total profit from discontinued operations in the year ended March 2018 was Rs 420.6 crore ($60.6 million), against a profit of Rs 10 crore ($1.4 million) from continuing operations on consolidated revenues of Rs 866 crore ($125 M).

At Strides alone, if 10 new subsidiaries were created in 2018, nine got divested, as per its annual report. The web of new entities never stops spinning.

“He works in so many areas and with so many companies that, at any point, a subset [of the business] is on a high even if the rest of the industry is on a downturn,” says a company insider who doesn’t want to be named as he isn’t authorised to speak with the media.  

Given all the deals that he has put together over the years, Kumar is arguably “one of the best entrepreneurs India has produced”, says a pharma executive, referring to the frequency of his transactions and distribution of wealth to partners and employees. He doesn’t want to be named because he’s done a several-crore deal with Strides in recent years. After the $1.65-billion sale of its injectables business to global generics giant Mylan Inc. in 2013, Strides returned $525 (pre-tax) million in dividends to shareholders. (Spoiler alert: Promoter groups hold 30.79%, as of March 2018). Additionally, Rs 300-odd crore (~$43 million) was shared with employees.

Kumar declined to be interviewed for this story. “I enjoy being reticent and reclusive. It’s done me good,” he wrote back over email.

In April 2018, Kumar, 58, returned from a one-year retirement-of-sorts to helm Strides again, the only company where he or his family office has a board-level representation. The global pharmaceutical industry headwinds had taken their toll, stocks were down 25%, and the mothership looked shaky.

Towards the end of January 2019, Strides made a string of buying-selling announcements. Curiously, it exited the Australian market, one where it had struck multiple lucrative deals in the past and was among the top three generics suppliers.


Seema Singh

Seema has over two decades of experience in journalism. Before starting The Ken, Seema wrote “Myth Breaker: Kiran Mazumdar-Shaw and the Story of Indian Biotech”, published by HarperCollins in May 2016. Prior to that, she was a senior editor and bureau chief for Bangalore with Forbes India, and before that she wrote for Mint. Seema has written for numerous international publications like IEEE-Spectrum, New Scientist, Cell and Newsweek. Seema is a Knight Science Journalism Fellow from the Massachusetts Institute of Technology and a MacArthur Foundation Research Grantee.

View Full Profile

Available exclusively to subscribers of The Ken India

This story is a part of The Ken India edition. Subscribe. Questions?


Annual Subscription

12-month access to 200+ stories, archive of 800+ stories from our India edition. Plus our premium newsletters, Beyond The First Order and The Nutgraf worth Rs. 99/month or $2/month each for free.

Rs. 2,750


Quarterly Subscription

3-month access to 60+ new stories with 3-months worth of archives from our India edition. Plus our premium newsletters, Beyond The First Order and The Nutgraf worth Rs. 99/month or $2/month each for free.

Rs. 1,750


Single Story

Instant access to this story for a year along with comment privileges.

Rs. 500


Annual Subscription

12-month access to 150+ stories from Southeast Asia.

$ 120


Quarterly Subscription

3-month access to 35+ stories from Southeast Asia.

$ 50


Single Story

Instant access to this story for a year along with comment privileges.

$ 20



What is The Ken?

The Ken is a subscription-only business journalism website and app that provides coverage across two editions - India and Southeast Asia.

What kind of stories do you write?

We publish sharp, original and reported stories on technology, business and healthcare. Our stories are forward-looking, analytical and directional — supported by data, visualisations and infographics.

We use language and narrative that is accessible to even lay readers. And we optimise for quality over quantity, every single time.

What do I get if I subscribe?

For subscribers of the India edition, we publish a new story every weekday, a premium daily newsletter, Beyond The First Order and a weekly newsletter - The Nutgraf.

For subscribers of the Southeast Asia edition, we publish a new story three days a week and a weekly newsletter, Strait Up.

The annual subscription will get you complete, exclusive access to our archive of previously published stories for your edition, along with access to our subscriber-only mobile apps, our premium comment sections, our newsletter archives and several other gifts and benefits.

Do I need to pay separately for your premium newsletters?

Nope. Paid, premium subscribers of The Ken get our newsletters delivered for free.

Does a subscription to the India edition grant me access to Southeast Asia stories? Or vice-versa?

Afraid not. Each edition is separate with its own subscription plan. The India edition publishes stories focused on India. The Southeast Asia edition is focused on Southeast Asia. We may occasionally cross-publish stories from one edition to the other.

Do you offer an all-access joint subscription for both editions?

Not yet. If you’d like to access both editions, you’ll have to purchase two subscriptions separately - one for India and the other for Southeast Asia.

Do you offer any discounts?

No. We have a zero discounts policy.

Is there a free trial I can opt for?

We don’t offer any trials, but you can sign up for a free account which will give you access to the weekly free story, our archive of free stories and summaries of the paid stories. You can stay on the free account as long as you’d like.

Do you offer refunds?

We allow you to sample our journalism for free before signing up, and after you do, we stand by its quality. But we do not offer refunds.

I am facing some trouble purchasing a subscription. What can I do?

Please write to us at [email protected] detailing the error or queries.